Amadea Britton

发表

Association Between 3 Doses of mRNA COVID-19 Vaccine and Symptomatic Infection Caused by the SARS-CoV-2 Omicron and Delta Variants.

S. Schrag, N. Shang, J. Verani, 2022, JAMA.

Use of 15-Valent Pneumococcal Conjugate Vaccine and 20-Valent Pneumococcal Conjugate Vaccine Among U.S. Adults: Updated Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

K. Poehling, H. Talbot, T. Pilishvili, 2022, MMWR. Morbidity and mortality weekly report.

Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 202

R. Link-Gelles, R. Wiegand, N. Shang, 2023, MMWR. Morbidity and mortality weekly report.

Association of COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection by Time Since Vaccination and Delta Variant Predominance.

S. Schrag, N. Shang, J. Verani, 2022, JAMA.

Association of Prior BNT162b2 COVID-19 Vaccination With Symptomatic SARS-CoV-2 Infection in Children and Adolescents During Omicron Predominance.

R. Link-Gelles, S. Schrag, N. Shang, 2022, JAMA.

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022

R. Link-Gelles, S. Schrag, R. Wiegand, 2022, MMWR. Morbidity and mortality weekly report.

Effectiveness of COVID-19 mRNA Vaccines in Preventing COVID-19-Associated Outpatient Visits and Hospitalizations Among American Indian and Alaska Native Persons, January–November 2021: A Test-Negative Case-Control Analysis Using Surveillance Data

L. Hammitt, M. McMorrow, R. Singleton, 2023, Open forum infectious diseases.

Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022

William F. Fadel, S. E. Reese, C. Mcevoy, 2022, MMWR. Morbidity and mortality weekly report.

Preliminary Estimates of Effectiveness of Monovalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection Among Children Aged 3–5 Years — Increasing Community Access to Testing Program, United States, July 2022–February 2023

R. Link-Gelles, R. Wiegand, N. Shang, 2023, MMWR. Morbidity and mortality weekly report.

Measuring the Association between Artemisinin-Based Case Management and Malaria Incidence in Southern Vietnam, 1991–2010

Tran Dang Nguyen, C. Buckee, M. F. Boni, 2015, The American journal of tropical medicine and hygiene.

Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut, December 2020–February 2021

S. Schrag, J. Jernigan, S. Parikh, 2021, MMWR. Morbidity and mortality weekly report.

Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023

H. Talbot, C. Kotton, S. Long, 2023, MMWR. Morbidity and mortality weekly report.

Systematic Review and Meta-Analysis of the Efficacy and Effectiveness of Pneumococcal Vaccines in Adults

Miwako Kobayashi, T. Pilishvili, Mahamoudou Ouattara, 2022, medRxiv.

Interim Recommendations for Use of Bivalent mRNA COVID-19 Vaccines for Persons Aged ≥6 Months — United States, April 2023

R. Link-Gelles, M. Daley, Danielle L. Moulia, 2023, MMWR. Morbidity and mortality weekly report.

Effectiveness of Homologous and Heterologous Covid-19 Boosters against Omicron

R. Link-Gelles, S. Schrag, N. Shang, 2022, The New England journal of medicine.

Humoral Immune Response to Messenger RNA Coronavirus Disease 2019 Vaccination Among Children Aged 5–11 Years in a Multisite Prospective Cohort Study, September 2021–September 2022

Lauren E. W. Olsho, K. Hegmann, A. Fowlkes, 2023, Open forum infectious diseases.

Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, December 2022–January 202

R. Link-Gelles, J. Verani, Emma K. Accorsi, 2023, Morbidity and Mortality Weekly Report.

Early Estimates of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-Circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023–January 2024

R. Link-Gelles, Clinton R. Paden, K. Fleming-Dutra, 2024, MMWR. Morbidity and mortality weekly report.